This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Fabian Kiessling (born 16 August 1972) is a German radiologist, university lecturer and author as well as a scientist in the field of molecular imaging.
Fabian Kiessling was born Mannheim and graduated high school in 1992 in Heidelberg and studied medicine at Heidelberg University. After his elective period at the district hospital in Schwetzingen, he completed his studies with the second state examination and was awarded his doctorate in 2001 in Internal Medicine. [1]
From 2001 he worked in the Dept. of Oncological Diagnostics and Therapy at the German Cancer Research Center (DKFZ) in Heidelberg and stayed there as an intern until 2002.
In 2003 he moved to the Dept. of Oncology at the Thorax Clinic Heidelberg and in parallel became head of the Molecular Diagnostics group in the Dept. of Medical Physics in Radiology at the DKFZ. In 2006, he became the Junior Group Leader for 'Molecular Imaging' at the DKFZ and habilitated in Experimental Radiology at the Heidelberg University.
2007 he completed his education as a medical specialist in diagnostic radiology.
In March 2008 he was appointed as full professor and director of the Institute for Experimental Molecular Imaging (ExMI) at RWTH Aachen (Rheinisch-Westfälische Technische Hochschule Aachen). He is also one of the directors of the RWTH Helmholtz Institute for Biomedical Engineering.
The research of Fabian Kiessling focusses on the development of new imaging methods and probes, with a particular focus on oncology and diseases that go along with angiogenesis and vascular remodeling. He worked on the imaging technique volumetric area detector computed tomography [2] and published the new ultrasound technique Motion Model Ultrasound Localization Microscopy together with his colleague Georg Schmitz. The ultrasound technique was preclinically tested and used in a first clinical application. [3] Both methods allow non-invasive imaging of hair-thin blood vessels in tumors and other tissues. In his translational research, imaging-guided therapy plays an important role including the investigation of biological barriers for drug delivery and the development of strategies to overcome these barriers by the use of nanomedicines, drug delivery systems, and other therapeutics.
{{cite book}}
: CS1 maint: others (link){{cite book}}
: CS1 maint: location missing publisher (link) CS1 maint: others (link){{cite book}}
: CS1 maint: location missing publisher (link) CS1 maint: others (link){{cite book}}
: CS1 maint: location missing publisher (link) CS1 maint: others (link)Medical ultrasound includes diagnostic techniques using ultrasound, as well as therapeutic applications of ultrasound. In diagnosis, it is used to create an image of internal body structures such as tendons, muscles, joints, blood vessels, and internal organs, to measure some characteristics or to generate an informative audible sound. The usage of ultrasound to produce visual images for medicine is called medical ultrasonography or simply sonography, or echography. The practice of examining pregnant women using ultrasound is called obstetric ultrasonography, and was an early development of clinical ultrasonography. The machine used is called an ultrasound machine, a sonograph or an echograph. The visual image formed using this technique is called an ultrasonogram, a sonogram or an echogram.
Medical physics deals with the application of the concepts and methods of physics to the prevention, diagnosis and treatment of human diseases with a specific goal of improving human health and well-being. Since 2008, medical physics has been included as a health profession according to International Standard Classification of Occupation of the International Labour Organization.
Medical imaging is the technique and process of imaging the interior of a body for clinical analysis and medical intervention, as well as visual representation of the function of some organs or tissues (physiology). Medical imaging seeks to reveal internal structures hidden by the skin and bones, as well as to diagnose and treat disease. Medical imaging also establishes a database of normal anatomy and physiology to make it possible to identify abnormalities. Although imaging of removed organs and tissues can be performed for medical reasons, such procedures are usually considered part of pathology instead of medical imaging.
A biopsy is a medical test commonly performed by a surgeon, an interventional radiologist, or an interventional cardiologist. The process involves the extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is then fixed, dehydrated, embedded, sectioned, stained and mounted before it is generally examined under a microscope by a pathologist; it may also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous or inflammatory conditions.
Articles related specifically to biomedical engineering include:
The Gottfried Wilhelm Leibniz Prize, or Leibniz Prize, is awarded by the German Research Foundation to "exceptional scientists and academics for their outstanding achievements in the field of research". Since 1986, up to ten prizes have been awarded annually to individuals or research groups working at a research institution in Germany or at a German research institution abroad. It is considered the most important research award in Germany.
Positron emission tomography–magnetic resonance imaging (PET–MRI) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging.
A breast biopsy is usually done after a suspicious lesion is discovered on either mammography or ultrasound to get tissue for pathological diagnosis. Several methods for a breast biopsy now exist. The most appropriate method of biopsy for a patient depends upon a variety of factors, including the size, location, appearance and characteristics of the abnormality. The different types of breast biopsies include fine-needle aspiration (FNA), vacuum-assisted biopsy, core needle biopsy, and surgical excision biopsy. Breast biopsies can be done utilizing ultrasound, MRI or a stereotactic biopsy imaging guidance. Vacuum assisted biopsies are typically done using stereotactic techniques when the suspicious lesion can only be seen on mammography. On average, 5–10 biopsies of a suspicious breast lesion will lead to the diagnosis of one case of breast cancer. Needle biopsies have largely replaced open surgical biopsies in the initial assessment of imaging as well as palpable abnormalities in the breast.
Christopher Heeschen is a German MD with a PhD. In 2004, he became a professor of Experimental Medicine and Department Head of Medicine at the University of Munich. He has worked at the Spanish National Cancer Research Centre (CNIO) since 2009.
Martin Zenke born August 7, 1953, in Korbach is a German biochemist, cell biologist, professor for cell biology and scientist, who is conducting research on stem cells and biomedical engineering.
Sanjiv Sam Gambhir was an American physician–scientist. He was the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. Additionally, he served as the Director of the Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection and the Precision Health and Integrated Diagnostics Center (PHIND). He authored 680 publications and had over 40 patents pending or granted. His work was featured on the cover of over 25 journals including the Nature Series, Science, and Science Translational Medicine. He was on the editorial board of several journals including Nano Letters, Nature Clinical Practice Oncology, and Science Translational Medicine. He was founder/co-founder of several biotechnology companies and also served on the scientific advisory board of multiple companies. He mentored over 150 post-doctoral fellows and graduate students from over a dozen disciplines. He was known for his work in molecular imaging of living subjects and early cancer detection.
Ferenc Andras Jolesz was a Hungarian-American physician and scientist best known for his research on image guided therapy, the process by which information derived from diagnostic imaging is used to improve the localization and targeting of diseased tissue to monitor and control treatment during surgical and interventional procedures. He pioneered the field of Magnetic Resonance Imaging-guided interventions and introduced of a variety of new medical procedures based on novel combinations of imaging and therapy delivery.
Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.
Ivo Meinhold-Heerlein is a German gynaecologist and obstetrician, honorary professor, university professor and deputy director of the Department of Gynaecology and Obstetrics at the University Hospital RWTH Aachen University. He is known for his work in the fields of molecular characterization of ovarian cancer.
Doris (Elfriede) Schachner née Korn was the first female German professor for Mineralogy and Honorary Senator of the RWTH Aachen University.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Jamshed Bomanji is a full professor, clinical lead, and head of the Institute of Nuclear medicine department at the University College Hospital (UCLH) NHS foundation trust based in London, UK.
Vicky Goh is a professor, chair of clinical cancer imaging, and head of cancer imaging department at the King's College London, England, United Kingdom. She joined King's College London in 2011. She is also a consultant radiologist at Guy's and St Thomas' Hospital in London.
Focused-ultrasound-mediated diagnostics or FUS-mediated diagnostics are an area of clinical diagnostic tools that use ultrasound to detect diseases and cancers. Although ultrasound has been used for imaging in various settings, focused-ultrasound refers to the detection of specific cells and biomarkers under flow combining ultrasound with lasers, microbubbles, and imaging techniques. Current diagnostic techniques for detecting tumors and diseases using biopsies often include invasive procedures and require improved accuracy, especially in cases such as glioblastoma and melanoma. The field of FUS-mediated diagnostics targeting cells and biomarkers is being investigated for overcoming these limitations.
Theranostics, also known as theragnostics, is a technique in personalised medicine and nuclear medicine where a one radioactive drug is used to identify (diagnose) and a second radioactive drug is used to treat cancerous tumors.